Mr. Christopher Karl Kruebbe, LCSW Clinical Social Worker Medicare: Accepting Medicare Assignments Practice Location: 9465 Third Street, Bay City, OR 97107 Phone: 541-450-7991 Fax: 541-472-0009 |
News Archive
CEFALY Technology announced today that its received U.S. Food and Drug Administration approval of the Cefaly medical device for the preventative treatment for migraine headaches. Cefaly is the first transcutaneous electrical nerve stimulation (TENS) device specifically authorized for use prior to the onset of pain. It is expected to be available in the U.S. in early April.
When doctors can't find a diagnosis for patient's disease, they turn to genetic detectives. Equipped with genomic sequencing technologies available for less than 10 years, these sleuths now routinely search through a patient's DNA looking for mutations responsible for mysterious diseases.
"The World Health Organization reports Guinea worm disease, which has plagued people for thousands of years, is on the verge of eradication," VOA News reports. "The U.N. agency says fewer than 400 cases of the infectious parasitic disease exist in four African countries, and that it will soon become only the second, after smallpox, to be wiped off the face of the earth," the news service writes.
Optimer Pharmaceuticals, Inc. today announced the pricing of a previously announced underwritten public offering of 6,000,000 shares of its common stock, offered at a price to the public of $11.25 per share. The gross proceeds to Optimer from this offering are expected to be $67.5 million, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by Optimer.
While smoking cigarettes appears to significantly increase a person's risk of developing multiple sclerosis, using Swedish snuff does not, according to a study published in the September 1, 2009, print issue of Neurology®, the medical journal of the American Academy of Neurology.
› Verified 4 days ago